Schwab Raises Debt To Restructure

Financial services company Charles Schwab is back under pressure today after announcing a significant restructuring. Like other stocks caught up in the “regional banking crisis” earlier this year, it has not fully recovered its decline and is now resuming lower. 📉

Yesterday it announced plans to shutter or downsize some real estate holdings and cut employee headcount to save at least $500 million annually. It’s also issuing 11-year debt at roughly 2% above Treasuries for “general corporate purposes,” as it’s estimating $400 to $500 million in restructuring costs in the year ahead. 

Investors remain concerned that competition from higher-yielding products is stealing deposits from Schwab and its competitors. Additionally, the firm reported lower net flows of client money as it integrated TD Ameritrade into its business. 💸

It’s not the only financial services giant to issue debt recently, as Bank of America, Goldman Sachs, Huntington Bancshares, and others have tapped the bond market recently. The entire sector remains under pressure for a variety of reasons. For example, today, S&P Global joined Moody’s in cutting several regional lenders’ credit ratings due to high commercial real estate (CRE) exposure. 🔻

$SCHW shares fell another 5% and are down about 20% over the past month as investors reassess the company’s overall financial health. 🕵️‍♂️

Learn More About...

Justice Department Targets UnitedHealth

With the upcoming presidential election looming, the current administration is itching to accomplish more before a potential shakeup. While antitrust regulators have had a field day with big tech, airlines, grocery chains, and others this year, they’re taking another look at UnitedHealth, especially given its recent cybersecurity issues. 🕵️‍♂️

The Justice Department is poking around to figure out the relationship between the company’s UnitedHealthcare insurance unit and its Optum health-services division. They’ve asked how UnitedHealth’s acquisitions of doctor groups might affect competitors and consumers. 🤔

Read It

Chinese Smartphone Maker Unveils EV

Chinese smartphone giant Xiaomi is entering the highly competitive electric vehicle (EV) market, revealing its first electric car this weekend. 👀

The consumer electronics company unveiled its SU7 sedan, which it says it spent more than $1.4 billion to develop. The vehicle is set to roll out in China next year and is attempting to do something Faraday Future and other competitors have failed to do: create a software-focused vehicle that matches the technology people find in their phones to what’s happening in their cars. 

Read It

Biotech Buyout Spree Continues

It may be the last week of the year, but many companies are rushing to get deals done before year-end. Two significant transactions in the biotech space were announced today, so let’s dive in. 👇

The first deal involves RayzeBio, which raised $358 million via an initial public offering (IPO) just three months ago. However, its time as a public company is being cut short by Bristol Myers Squibb, which is acquiring the radiopharmaceutical therapeutics company for $62.50 per share in cash. 💰

Read It

Japan’s Nippon Takes Over U.S. Steel

After months of bidding, U.S. Steel finally has a buyer. However, the auction’s winner has some parties concerned. 🤔

Japan’s Nippon Steel emerged as the top bidder for the 122-year-old steelmaker, beating out offers from Cleveland-Cliffs, ArcelorMittal, and Nucor. Its $55 per share price represents a 142% premium to where $X shares were trading before Cleveland-Cliffs’ $35-per-share offer kicked off the bidding war.

Read It